Dr. Berdeja on Updated CARTITUDE-1 Results in Multiple Myeloma

Jesus Berdeja, MD, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

Twenty-nine patients were enrolled in the phase 1b portion of the trial, says Berdeja. Eligibility criteria for CARTITUDE-1 included measurable and progressive disease; an ECOG performance status of less than 1; at least 3 prior therapies or double-refractory status; and prior treatment with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy. Patients were heavily pretreated, having received a median of 5 prior lines of therapy. Additionally, 86% of patients were triple refractory, says Berdeja.

According to updated results, the overall response rate was 100%, with a stringent complete response rate of 86% (25 out of 29 patients). The estimated progression-free survival at 9 months was 86%. Additionally, no unexpected safety signals were reported, says Berdeja. The majority of patients experienced grade 1/2 cytokine release syndrome (CRS) with a median time to onset of 7 days. Neurotoxicity was rare, says Berdeja. All-grade neurotoxicity was observed in 10% of patients, with 3% of patients having grade 3 or higher toxicity. The most frequent adverse events were neutropenia (100%), CRS (93%), and thrombocytopenia (86%). However, most cytopenias resolved within 60 days, says Berdeja.

At a median follow-up of 11.5 months, 22 of 29 patients were alive and progression-free. Additionally, of the 16 patients with a complete response who were evaluable for minimal residual disease (MRD) assessment, 81% and 69% were MRD negative at sensitivities of 10-5 and 10-6, respectively.

Related Videos
Guillermo Garcia-Manero, MD
Amer Zeidan, MBBS
Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania
Jeffery Zonder, MD
Natalie S. Callander, MD
Jeffery Zonder, MD
Susan Bal, MD
Michael J. Fallon, MD
Andrew Kin, MD
Marilena Tauro, PhD
Related Content